Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | F7 | P08709 | 3/20 | 0.43 |
| ▸ | F3 | P13726 | 3/20 | 0.43 |
| ▸ | FABP3 | P05413 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GNA15 | P30679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895153 | 0.83 | EPHX2 (0.45) | DUSP3FFAR1LMNAFABP4ALOX15 | |
| SCHEMBL8969118 | 0.83 | EPHX2 (0.45) | DUSP3FFAR1LMNAFABP4ALOX15 | |
| SCHEMBL31374704 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL10008604 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL10008598 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL14935167 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL12186603 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL12186770 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL19692318 | 0.79 | EPHX2 (0.47) | F7F3FABP3PPARGPPARD | |
| SCHEMBL977421 | 0.79 | EPHX2 (0.47) | F7F3FABP3PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281562-A1 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | The University of British Columbia (CA) | 2023-11-29 | — | — | EP | claimed |
| WO-2023161873-A1 | GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS | INCISIVE GENETICS, INC. (CA) | 2023-08-31 | — | — | WO | claimed |
| EP-4395748-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395820-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4387592-A1 | VACCINE COMPOSITIONS | Monash University (AU) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024068545-A1 | INFLUENZA VIRUS VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-04 | — | — | WO | disclosed |
| EP-4334446-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4313152-A1 | IMMUNOGENIC COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-02-07 | — | — | EP | disclosed |
| EP-4312988-A2 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | CureVac SE (DE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2010148013-A2 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147992-A1 | METHODS FOR INCREASING EFFICACY OF LIPID FORMULATED SIRNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2245039-A2 | OPTIMIZED METHODS FOR DELIVERY OF DSRNA TARGETING THE PCSK9 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010105372-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS C VIRUS EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010099341-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MIG-12 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010057217-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELLULAR UPTAKE OF RNAI VIA SID-1 | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010048228-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010036962-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009134487-A2 | OPTIMIZED METHODS FOR DELIVERY OF DSRNA TARGETING THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |